---
document_datetime: 2026-01-23 17:55:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ronapreve.html
document_name: ronapreve.html
version: success
processing_time: 0.1252154
conversion_datetime: 2026-01-26 20:31:12.930663
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ronapreve

[RSS](/en/individual-human-medicine.xml/67510)

##### Withdrawn

This medicine's authorisation has been withdrawn

casirivimab / imdevimab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ronapreve](#news-on)
- [Related content](#related-content-72346)
- [More information on Ronapreve](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 5 December 2025, the European Commission withdrew the marketing authorisation for Ronapreve (casirivimab / imdevimab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Roche Registration GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Ronapreve was granted marketing authorisation in the EU on 12 November 2021 for the prevention and treatment of COVID-19. The marketing authorisation was initially valid for a 5-year period.

Other [COVID-19 medicines](https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines) are available throughout the EU.

Ronapreve : EPAR - Medicine overview

Reference Number: EMA/47158/2025

English (EN) (131.04 KB - PDF)

**First published:** 12/11/2021

**Last updated:** 23/01/2026

[View](/en/documents/overview/ronapreve-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-443)

български (BG) (171.1 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/bg/documents/overview/ronapreve-epar-medicine-overview_bg.pdf)

español (ES) (132.14 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/es/documents/overview/ronapreve-epar-medicine-overview_es.pdf)

čeština (CS) (156.44 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/cs/documents/overview/ronapreve-epar-medicine-overview_cs.pdf)

dansk (DA) (131.45 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/da/documents/overview/ronapreve-epar-medicine-overview_da.pdf)

Deutsch (DE) (137.38 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/de/documents/overview/ronapreve-epar-medicine-overview_de.pdf)

eesti keel (ET) (128.27 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/et/documents/overview/ronapreve-epar-medicine-overview_et.pdf)

ελληνικά (EL) (173.87 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/el/documents/overview/ronapreve-epar-medicine-overview_el.pdf)

français (FR) (133.75 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/fr/documents/overview/ronapreve-epar-medicine-overview_fr.pdf)

hrvatski (HR) (154.52 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/hr/documents/overview/ronapreve-epar-medicine-overview_hr.pdf)

italiano (IT) (129.8 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/it/documents/overview/ronapreve-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (163.01 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/lv/documents/overview/ronapreve-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (154.17 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/lt/documents/overview/ronapreve-epar-medicine-overview_lt.pdf)

magyar (HU) (157.52 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/hu/documents/overview/ronapreve-epar-medicine-overview_hu.pdf)

Malti (MT) (156.9 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/mt/documents/overview/ronapreve-epar-medicine-overview_mt.pdf)

Nederlands (NL) (134.59 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/nl/documents/overview/ronapreve-epar-medicine-overview_nl.pdf)

polski (PL) (159.95 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/pl/documents/overview/ronapreve-epar-medicine-overview_pl.pdf)

português (PT) (131.4 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/pt/documents/overview/ronapreve-epar-medicine-overview_pt.pdf)

română (RO) (161.99 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/ro/documents/overview/ronapreve-epar-medicine-overview_ro.pdf)

slovenčina (SK) (156.34 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/sk/documents/overview/ronapreve-epar-medicine-overview_sk.pdf)

slovenščina (SL) (153.49 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/sl/documents/overview/ronapreve-epar-medicine-overview_sl.pdf)

Suomi (FI) (127.25 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/fi/documents/overview/ronapreve-epar-medicine-overview_fi.pdf)

svenska (SV) (129.77 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/sv/documents/overview/ronapreve-epar-medicine-overview_sv.pdf)

Ronapreve : EPAR - Risk-management-plan

English (EN) (1.23 MB - PDF)

**First published:** 19/11/2021

**Last updated:** 23/01/2026

[View](/en/documents/rmp/ronapreve-epar-risk-management-plan_en.pdf)

## Product information

Ronapreve : EPAR - Product information

English (EN) (642.65 KB - PDF)

**First published:** 12/11/2021

**Last updated:** 23/01/2026

[View](/en/documents/product-information/ronapreve-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-238)

български (BG) (952.28 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/bg/documents/product-information/ronapreve-epar-product-information_bg.pdf)

español (ES) (667.61 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/es/documents/product-information/ronapreve-epar-product-information_es.pdf)

čeština (CS) (837.67 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/cs/documents/product-information/ronapreve-epar-product-information_cs.pdf)

dansk (DA) (763 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/da/documents/product-information/ronapreve-epar-product-information_da.pdf)

Deutsch (DE) (764.1 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/de/documents/product-information/ronapreve-epar-product-information_de.pdf)

eesti keel (ET) (646.76 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/et/documents/product-information/ronapreve-epar-product-information_et.pdf)

ελληνικά (EL) (1009.66 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/el/documents/product-information/ronapreve-epar-product-information_el.pdf)

français (FR) (659.75 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/fr/documents/product-information/ronapreve-epar-product-information_fr.pdf)

hrvatski (HR) (718.58 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/hr/documents/product-information/ronapreve-epar-product-information_hr.pdf)

íslenska (IS) (669.58 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/is/documents/product-information/ronapreve-epar-product-information_is.pdf)

italiano (IT) (823.21 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/it/documents/product-information/ronapreve-epar-product-information_it.pdf)

latviešu valoda (LV) (860.54 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/lv/documents/product-information/ronapreve-epar-product-information_lv.pdf)

lietuvių kalba (LT) (731.02 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/lt/documents/product-information/ronapreve-epar-product-information_lt.pdf)

magyar (HU) (742.37 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/hu/documents/product-information/ronapreve-epar-product-information_hu.pdf)

Malti (MT) (784.47 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/mt/documents/product-information/ronapreve-epar-product-information_mt.pdf)

Nederlands (NL) (799.15 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/nl/documents/product-information/ronapreve-epar-product-information_nl.pdf)

norsk (NO) (613.07 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/no/documents/product-information/ronapreve-epar-product-information_no.pdf)

polski (PL) (780.11 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/pl/documents/product-information/ronapreve-epar-product-information_pl.pdf)

português (PT) (757.16 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/pt/documents/product-information/ronapreve-epar-product-information_pt.pdf)

română (RO) (755.8 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/ro/documents/product-information/ronapreve-epar-product-information_ro.pdf)

slovenčina (SK) (787.92 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/sk/documents/product-information/ronapreve-epar-product-information_sk.pdf)

slovenščina (SL) (671.93 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/sl/documents/product-information/ronapreve-epar-product-information_sl.pdf)

Suomi (FI) (693.36 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/fi/documents/product-information/ronapreve-epar-product-information_fi.pdf)

svenska (SV) (678.32 KB - PDF)

**First published:**

12/11/2021

**Last updated:**

23/01/2026

[View](/sv/documents/product-information/ronapreve-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254621 03/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ronapreve : EPAR - All authorised presentations

English (EN) (34.54 KB - PDF)

**First published:** 19/11/2021

**Last updated:** 23/01/2026

[View](/en/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-40)

български (BG) (60.75 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/bg/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_bg.pdf)

español (ES) (32.84 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/es/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.65 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/cs/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (35.17 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/da/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34.93 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/de/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35.12 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/et/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.74 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/el/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_el.pdf)

français (FR) (32.88 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/fr/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.1 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/hr/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (35.02 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/is/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_is.pdf)

italiano (IT) (33.72 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/it/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (54.86 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/lv/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.95 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/lt/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.06 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/hu/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (59.14 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/mt/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (31.96 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/nl/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (34.79 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/no/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.62 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/pl/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_pl.pdf)

português (PT) (36.26 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/pt/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.49 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/ro/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.44 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/sk/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.27 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/sl/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.31 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/fi/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.62 KB - PDF)

**First published:**

19/11/2021

**Last updated:**

23/01/2026

[View](/sv/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ronapreve Active substance

- casirivimab
- imdevimab

International non-proprietary name (INN) or common name

- casirivimab
- imdevimab

Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J06BD07

### Pharmacotherapeutic group

Immune sera and immunoglobulins

### Therapeutic indication

Ronapreve is indicated for: - Treatment of COVID-19 in adults, adolescents and children aged 2 years and older weighing at least 10 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. - Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result. - Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg. Ronapreve should be used in accordance with official recommendations where available and based on information on the activity of casirivimab and imdevimab against presently circulating viral variants.

## Authorisation details

EMA product number EMEA/H/C/005814 Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 11/11/2021 Marketing authorisation issued 12/11/2021 Withdrawal of marketing authorisation 05/12/2025 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ronapreve : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (344.81 KB - PDF)

**First published:** 03/04/2025

**Last updated:** 23/01/2026

[View](/en/documents/procedural-steps-after/ronapreve-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ronapreve : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (182 KB - PDF)

**First published:** 18/03/2022

**Last updated:** 23/01/2026

[View](/en/documents/procedural-steps-after/ronapreve-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ronapreve-H-C-005814-II-0017 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/104963/2025

English (EN) (5.9 MB - PDF)

**First published:** 09/04/2025

**Last updated:** 23/01/2026

[View](/en/documents/variation-report/ronapreve-h-c-005814-ii-0017-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ronapreve (II-17)

Adopted

Reference Number: EMA/516539/2024

English (EN) (149.54 KB - PDF)

**First published:** 31/01/2025

**Last updated:** 23/01/2026

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ronapreve-ii-17_en.pdf)

Ronapreve-H-C-5814-II-0002 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/68947/2023

English (EN) (21.19 MB - PDF)

**First published:** 10/07/2023

**Last updated:** 23/01/2026

[View](/en/documents/variation-report/ronapreve-h-c-5814-ii-0002-epar-assessment-report_en.pdf)

Ronapreve-H-C-5814-P46-017 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/57025/2023

English (EN) (504.13 KB - PDF)

**First published:** 28/04/2023

**Last updated:** 23/01/2026

[View](/en/documents/variation-report/ronapreve-h-c-5814-p46-017-epar-assessment-report_en.pdf)

Ronapreve-H-C-5814-P46-016 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/57024/2023

English (EN) (1.22 MB - PDF)

**First published:** 28/04/2023

**Last updated:** 23/01/2026

[View](/en/documents/variation-report/ronapreve-h-c-5814-p46-016-epar-assessment-report_en.pdf)

Ronapreve-H-C-5814-P46-015 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/57023/2023

English (EN) (706.5 KB - PDF)

**First published:** 28/04/2023

**Last updated:** 23/01/2026

[View](/en/documents/variation-report/ronapreve-h-c-5814-p46-015-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Ronapreve (II-02)

Adopted

Reference Number: EMA/CHMP/80241/2023

English (EN) (152.52 KB - PDF)

**First published:** 26/04/2023

**Last updated:** 23/01/2026

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ronapreve-ii-02_en.pdf)

Ronapreve-H-C-5814-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/902731/2022

English (EN) (3.81 MB - PDF)

**First published:** 21/12/2022

**Last updated:** 23/01/2026

[View](/en/documents/variation-report/ronapreve-h-c-5814-p46-005-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Ronapreve : EPAR - Public assessment report

Adopted

Reference Number: EMA/680189/2021

English (EN) (7.91 MB - PDF)

**First published:** 19/11/2021

**Last updated:** 23/01/2026

[View](/en/documents/assessment-report/ronapreve-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ronapreve

Adopted

Reference Number: EMA/CHMP/629963/2021

English (EN) (140.89 KB - PDF)

**First published:** 11/11/2021

**Last updated:** 23/01/2026

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ronapreve_en.pdf)

#### News on Ronapreve

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2025) 31/01/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

[ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2](/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2) 09/12/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

[COVID-19: EMA recommends authorisation of two monoclonal antibody medicines](/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines) 11/11/2021

#### Related content

- [Emergency Task Force (ETF) documents: COVID-19](/en/committees/working-parties-other-groups/emergency-task-force-etf/emergency-task-force-etf-recommendations#covid-19-66890)

#### More information on Ronapreve

- [EMEA-002964-PIP01-21-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002964-pip01-21-m02)
- [EMEA-002965-PIP01-21-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002965-pip01-21-m02)
- [A secondary data use study of pregnancy and infant outcomes following administration of casirivimab + imdevimab (Ronapreve, REGEN-COV) during pregnancy based on data obtained from the COVID-19 international drug pregnancy registry [COVID-PR] - post-authorisation study](https://catalogues.ema.europa.eu/study/46116)

**This page was last updated on** 23/01/2026

## Share this page

[Back to top](#main-content)